Literature DB >> 11130352

Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose?

S R Lenton1, K M Hargreaves.   

Abstract

Heroin overdose is a major cause of death among heroin users, and often occurs in the company of other users. However, sudden death after injection is rare, giving ample opportunity for intervention. Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. A trial could be conducted to determine whether this intervention improves the management of overdose or results in a net increase in harm (by undermining existing prevention strategies, precipitating naloxone-related complications, or resulting in riskier heroin use).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11130352

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  14 in total

Review 1.  Strategies for preventing heroin overdose.

Authors:  Karl A Sporer
Journal:  BMJ       Date:  2003-02-22

Review 2.  Flumazenil, naloxone and the 'coma cocktail'.

Authors:  Marco L A Sivilotti
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

3.  Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study.

Authors:  Karen H Seal; Robert Thawley; Lauren Gee; Joshua Bamberger; Alex H Kral; Dan Ciccarone; Moher Downing; Brian R Edlin
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

4.  Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration.

Authors:  Debra Kerr; Paul Dietze; Anne-Maree Kelly; Damien Jolley
Journal:  J Urban Health       Date:  2008-03-18       Impact factor: 3.671

5.  Prediction Model for Two-Year Risk of Opioid Overdose Among Patients Prescribed Chronic Opioid Therapy.

Authors:  Jason M Glanz; Komal J Narwaney; Shane R Mueller; Edward M Gardner; Susan L Calcaterra; Stanley Xu; Kristin Breslin; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2018-01-29       Impact factor: 5.128

6.  Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention.

Authors:  Peter J Davidson; Rachel L McLean; Alex H Kral; Alice A Gleghorn; Brian R Edlin; Andrew R Moss
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

7.  Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City.

Authors:  Phillip O Coffin; Crystal Fuller; Liza Vadnai; Shannon Blaney; Sandro Galea; David Vlahov
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

8.  Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area.

Authors:  Karen H Seal; Moher Downing; Alex H Kral; Shannon Singleton-Banks; Jon-Paul Hammond; Jennifer Lorvick; Dan Ciccarone; Brian R Edlin
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

Review 9.  Heroin overdose: research and evidence-based intervention.

Authors:  Shane Darke; Wayne Hall
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

10.  Racial/ethnic disparities in overdose mortality trends in New York City, 1990-1998.

Authors:  Sandro Galea; Jennifer Ahern; Ken Tardiff; Andy Leon; Phillip O Coffin; Karen Derr; David Vlahov
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.